| MHC class I antigens, immune surveillance, and tumor immune escape A Garcia‐Lora, I Algarra, F Garrido Journal of cellular physiology 195 (3), 346-355, 2003 | 668 | 2003 |
| The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape I Algarra, A García-Lora, T Cabrera, F Ruiz-Cabello, F Garrido Cancer Immunology, Immunotherapy 53, 904-910, 2004 | 394 | 2004 |
| A new extract of the plant calendula officinalis produces a dual in vitroeffect: cytotoxic anti-tumor activity and lymphocyte activation E Jiménez-Medina, A Garcia-Lora, L Paco, I Algarra, A Collado, F Garrido BMC câncer 6, 1-14, 2006 | 306 | 2006 |
| MHC class I antigens and immune surveillance in transformed cells N Aptsiauri, T Cabrera, A Garcia‐Lora, MA Lopez‐Nevot, F Ruiz‐Cabello, ... International review of cytology 256, 139-189, 2007 | 177 | 2007 |
| The immunomodulator PSK induces in vitro cytotoxic activity in tumour cell lines via arrest of cell cycle and induction of apoptosis E Jiménez-Medina, E Berruguilla, I Romero, I Algarra, A Collado, ... BMC cancer 8, 1-10, 2008 | 129 | 2008 |
| The escape of cancer from T lymphocytes: immunoselection of MHC class I loss variants harboring structural-irreversible “hard” lesions F Garrido, I Algarra, AM García-Lora Cancer immunology, immunotherapy 59, 1601-1606, 2010 | 127 | 2010 |
| MHC class I‐deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components A Garcia‐Lora, M Martinez, I Algarra, JJ Gaforio, F Garrido International journal of cancer 106 (4), 521-527, 2003 | 124 | 2003 |
| Immunoselection by T lymphocytes generates repeated MHC class I‐deficient metastatic tumor variants A Garcia‐Lora, I Algarra, JJ Gaforio, F Ruiz‐Cabello, F Garrido International journal of cancer 91 (1), 109-119, 2001 | 102 | 2001 |
| MHC class I molecules act as tumor suppressor genes regulating the cell cycle gene expression, invasion and intrinsic tumorigenicity of melanoma cells C Garrido, L Paco, I Romero, E Berruguilla, J Stefansky, A Collado, ... Carcinogenesis 33 (3), 687-693, 2012 | 98 | 2012 |
| Metastases in immune-mediated dormancy: a new opportunity for targeting cancer I Romero, F Garrido, AM Garcia-Lora Cancer research 74 (23), 6750-6757, 2014 | 88 | 2014 |
| Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations N Aptsiauri, R Carretero, A Garcia-Lora, LM Real, T Cabrera, F Garrido Cancer Immunology, Immunotherapy 57, 1727-1733, 2008 | 85 | 2008 |
| HLA and melanoma: multiple alterations in HLA class I and II expression in human melanoma cell lines from ESTDAB cell bank R Mendez, N Aptsiauri, A Del Campo, I Maleno, T Cabrera, ... Cancer immunology, immunotherapy 58, 1507-1515, 2009 | 80 | 2009 |
| T lymphocytes restrain spontaneous metastases in permanent dormancy I Romero, C Garrido, I Algarra, A Collado, F Garrido, AM Garcia-Lora Cancer research 74 (7), 1958-1968, 2014 | 76 | 2014 |
| Tumour immunology, vaccination and escape strategies A García‐Lora, I Algarra, A Collado, F Garrido European journal of immunogenetics 30 (3), 177-183, 2003 | 76 | 2003 |
| Molecular characterization of congenital myasthenic syndromes in Spain D Natera-de Benito, A Töpf, JJ Vilchez, L González-Quereda, ... Neuromuscular Disorders 27 (12), 1087-1098, 2017 | 59 | 2017 |
| The tumour suppressor Fhit positively regulates MHC class I expression on cancer cells I Romero, M Martinez, C Garrido, A Collado, I Algarra, F Garrido, ... The Journal of pathology 227 (3), 367-379, 2012 | 55 | 2012 |
| Generation of MHC class I diversity in primary tumors and selection of the malignant phenotype F Garrido, I Romero, N Aptsiauri, AM Garcia‐Lora International journal of cancer 138 (2), 271-280, 2016 | 53 | 2016 |
| Different regulation of PKC isoenzymes and MAPK by PSK and IL-2 in the proliferative and cytotoxic activities of the NKL human natural killer cell line A García-Lora, M Martinez, S Pedrinaci, F Garrido Cancer Immunology, Immunotherapy 52, 59-64, 2003 | 52 | 2003 |
| Immunotherapy eradicates metastases with reversible defects in MHC class I expression C Garrido, I Romero, E Berruguilla, B Cancela, I Algarra, A Collado, ... Cancer Immunology, Immunotherapy 60, 1257-1268, 2011 | 43 | 2011 |
| Long-term follow-up in patients with congenital myasthenic syndrome due to RAPSN mutations D Natera-de Benito, M Bestué, JJ Vilchez, T Evangelista, A Töpf, ... Neuromuscular Disorders 26 (2), 153-159, 2016 | 42 | 2016 |
